Industry Workshops
Sunday, September 9, 2012
IWSB600 Breakfast Workshop – Seventh Annual Business of Pathology Review
6:30–7:45 am
CME/CE NOT APPLICABLE
This section will focus on the factors that are changing revenue methodology in pathology today.
- Managed Care Contracting
- Accountable Care Organizations
- Trends in the business of pathology
Vachette Pathology will provide real-world examples from the auditing trenches and present concrete solutions to enhance the revenue of your practice.
Presented by 
IWSB601 Breakfast Workshop – Integrating Genomics with Clinicopathologic Measures
6:30–7:45 am
CME/CE NOT APPLICABLE
TThis session will review controversies and issues surrounding the diagnosis of ductal carcinoma in situ (DCIS) in patients. It will present data comparing molecular tools with clinicopathologic features in assessing the risk of local recurrence for DCIS patients and describe the clinical implications for risk assessment of DCIS.
Speaker: Sunil Badve, MD
Presented by 
IWSB602 Breakfast Workshop – Clinical Impact of Using Multiple Antibodies to Aid in the Critical Diagnosis of Breast Cancer
6:30–7:45 am
CME/CE NOT APPLICABLE
The need for highly sensitive, accurate testing of pathologic specimens has become essential to the histopathology laboratory. With the advent of genomic testing, including PCR and microarray technologies, the already limited tissue biopsy is in high demand. The ability to use multiple antibodies to ascertain a diagnosis on a single slide has proved to be an integral tool, with the key feature being the conservation of precious patient tissue. This workshop will review the use of multiple antibodies in the assessment and diagnosis of breast cancers, and how the combination of these antibodies on a single slide help to demystify what could otherwise have been a challenging diagnosis over multiple slides.
Presenter: David G. Hicks, MD, FCAP
Presented by 
IWSB603 Breakfast Workshop – Integrating CancerTYPE ID into the Diagnostic Algorithm as a Complementary Tool to IHC in Difficult-to-Diagnose Metastatic Cancer
6:30–7:45 am
CME/CE NOT APPLICABLE
Molecular cancer classification is an emerging diagnostic complement to pathologic review for difficult-to-diagnose tumors. This workshop will overview CancerTYPE ID, including an “inside the black box” look at how the test works, new clinical study data comparing IHC to CancerTYPE ID, and a discussion of how these data may inform decisions of when to use molecular classification in your practice.
Presented by 
Monday, September 10, 2012
IWMB700 Regulatory Toolkit: 2012
6:30–7:45 am
CME/CE NOT APPLICABLE
Pathology continues to face an array of governmental initiatives that have the potential to negatively impact pathology groups. For many groups, finding a path through health care reform has become a major challenge. Identifying current issues, assessing the potential impact, and developing a strategic plan are steps that this workshop will address, as well as ways to capitalize on opportunities in the current environment.
Presented by 
IWMB701 Breakfast Workshop – The Pathwork® Tissue of Origin Test and Immunohistochemistry: Determining the Primary Site of Metastatic Cancer
6:30–7:45 am
CME/CE NOT APPLICABLE
The FDA-cleared Tissue of Origin Test determines the most likely tissue of origin by comparing the gene expression profile of FFPE tumor tissue to expression patterns of 15 known tumor types. This study compares the effectiveness of gene expression testing and immunohistochemistry in providing a diagnosis.
Presented by 
IWMB702 Breakfast Workshop – Agilent & Dako: Uniting Anatomical and Molecular Pathology
6:30–7:45 am
CME/CE NOT APPLICABLE
In this two-part workshop, you will hear how Dako and Agilent have come together as the only company to offer a breadth of technologies for both anatomical and molecular pathology.
Learn how Washington University is using the most advanced genomics technologies for molecular pathology research, including Agilent’s market-leading products in next-generation sequencing target enrichment for Mutation Analysis, and SureFISH, the most comprehensive menu of oligo FISH probes for Copy Number Analysis.
You will also learn about the new capabilities and offerings of the combined company, including the most trusted microarray for cytogenetic research, antibodies, and products for H&E and IHC.
Presented by 
Monday, September 10, 2012
IWMD900 Dinner Workshop – The Essential Role of a Pathologist in the Era of Personalized Medicine
6:15 pm
CME/CE NOT APPLICABLE
This session will cover how new companion diagnostics and other pivotal genetic markers can be incorporated into standard pathology evaluations.
Presented by 
IWMD910 Dinner Workshop –Enabling more Confident Decisions for Cancer Treatment
6:15 pm
CME/CE NOT APPLICABLE
Presented by 
IWMD920 Dinner Workshop –Workup of the Abnormal CBC in the Molecular Era: Algorithms and Recommendations for Additional Testing in Diagnosing Benign and Neoplastic Hematologic Conditions in Blood
6:15 pm
CME/CE NOT APPLICABLE
The complete blood count (CBC) is very often the initial diagnostic test for patients presenting with a variety of neoplastic and nonneoplastic conditions. Therefore, the pathologist and the hematology laboratory play a critical role in detecting disease and advancing the diagnostic workup of cancer and benign hematologic conditions. A large number of new testing methodologies, including sensitive and specific molecular and proteomic assays, are emerging. This session will discuss algorithms for diagnosis and make recommendations for workups of leukocytosis, cytopenias, coagulopathy and hemoglobinopathies. Recommendations on which conditions require a bone marrow evaluation or other tissue testing for diagnosis will also be discussed.
Presented by 
Tuesday, September 11, 2012
IWTD800 Dinner Workshop – Recent Advances in Prognostic Risk-of-Recurrence for Early Stage NSCLC – New Pinpoint Assay
6:00 pm
CME/CE NOT APPLICABLE
Life Technologies will discuss clinical evidence to support the launch of its Pinpoint Early-Stage NSCLC Risk of Recurrence Assay. As the leading cause of cancer deaths worldwide, lung cancer claims close to 1.5 million lives every year. Although medical research has realized impressive gains against many forms of cancer, the survival rate for lung cancer has not changed in 30 years, with nearly half of the early-stage patients not surviving beyond five years. This situation could benefit from better differential diagnosis and more efficient treatment protocols. The Pinpoint lung cancer test was validated in a CLIA-certified environment using two independent, blinded retrospective studies of approximately 1,500 patients, a significantly powered study compared to studies used to launch other proprietary diagnostic tests available in other cancer areas today. Using formalin-fixed, paraffin-embedded tumor specimens, this quantitative PCR test screens for expression using a proprietary 14-gene panel. The blinded studies demonstrated that the test reliably identifies early stage non-small cell lung cancer (NSCLC) patients at high risk for mortality following surgery. By utilizing the Pinpoint test, pathologists will be able to identify which patients have a high chance of recurrence and assist their clinical colleagues to direct more aggressive patient management. The Pinpoint gene panel was developed on a Life qPCR platform and can be transitioned from a CLIA LDT to an IVD/CE Marked kit.
Presented by 